Patients with MASLD had nearly twice the all-cause mortality rate as the general population, suggesting the need for ...

The chief executive of German technology giant Siemens on Monday said international commerce will continue despite massive ...

Received a "Study May Proceed” letter from the FDA to evaluate amezalpat in combination with atezolizumab (TECENTRIQ®) and ...

Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement ...

TriSalus Life Sciences, Inc. ( NASDAQ: TLSI) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Jeremy Feffer - Managing Director, LifeSci Advisors Mary Szela - President & Chief Executive ...

Q4 2024 Earnings Call Transcript March 27, 2025 TriSalus Life Sciences, Inc. reports earnings inline with expectations. Reported EPS is $-0.35 EPS, expectations were $-0.35. Operator: Good morning, ...

Despite the Constitution not allowing for any person to be elected to two terms as president of the United States, President ...

You'll probably have a blood test for the marker AFP at every visit if you had hepatocellular carcinoma (HCC). You may also have blood tests ... Sharing your worries can mean they don’t seem so ...

A multimillion-pound plan to build three new care homes – including one in the New Forest – has been scrapped by Hampshire ...

Part 1 yesterday covered key tradeoffs and the first two of four categories of strategies that have been advanced to improve ...

Granted both Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration (FDA) for amezalpat for the treatment of patients with HCC. Received a “Study May Proceed” letter ...